HHS May Pursue New Drug Pricing Policies Not In Blueprint

HHS might take actions to rein in drug prices not posed in the administration’s blueprint given recent price hikes by drug makers, a top HHS official said Tuesday (July 10). The official did not say what those policies may be, but said they won’t include Medicare price negotiation or any form of price controls. President Donald Trump lashed out at drug makers Monday and threatened retaliation after Pfizer and a number of other drug companies announced list price increases for...